BSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Boston Scientific Corp (BSX) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company demonstrates solid financial growth and has a strong position in the MedTech sector, the recent lawsuits, insider selling, and lack of significant positive trading signals suggest caution. Additionally, the technical indicators show bearish trends, and the stock has no immediate catalysts to drive significant upside in the short term. Holding off on investment until more clarity emerges or the stock shows stronger positive momentum would be prudent.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 47.045, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock closed below the pivot level of 62.981, suggesting weakness. Key support levels are at 61.082 and 59.91, with resistance at 64.88 and 66.052.
Strong Q4 2025 financial performance with revenue up 15.90% YoY, net income up 18.94% YoY, and EPS up 18.42% YoY.
Analysts maintain mostly positive ratings with several 'Buy' and 'Outperform' recommendations, citing strong fundamentals and stable end markets.
The CHAMPION-AF trial results, while not groundbreaking, are expected to support incremental growth in WATCHMAN procedures.
Multiple class action lawsuits alleging securities fraud and misrepresentation, which could weigh on investor sentiment.
Insider selling has increased significantly by 755.62% over the last month.
Analysts have broadly lowered price targets due to sector-wide multiple compression and concerns over growth in key areas.
The stock shows bearish technical trends and lacks immediate upward momentum.
In Q4 2025, Boston Scientific demonstrated strong growth with revenue increasing by 15.90% YoY to $5.29 billion, net income rising by 18.94% YoY to $672 million, and EPS improving by 18.42% YoY to $0.45. Gross margin also increased to 65.38%, up 3.76% YoY.
Analysts maintain a generally positive outlook with 'Buy' and 'Outperform' ratings, but many have lowered price targets recently due to sector-wide multiple compression and concerns over growth in key areas. Current price targets range from $80 to $105, with a median target of approximately $90.
